1,053 results on '"Parecoxib"'
Search Results
2. Preemptive Analgesic Efficacy of Parecoxib for Reducing Postoperative Pain in Gynecological Surgery
- Published
- 2024
3. Efficacy and Safety of Parecoxib vs. Indomethacin in Preventing Post-ERCP Pancreatitis (PRECISE)
- Author
-
Ge Yu, Attending Physician, Gastroenterology Department
- Published
- 2024
4. Bioequivalence of Two Formulations of Parecoxib in Healthy Volunteers Under Fasting Conditions
- Published
- 2024
5. Evaluation of the Safety and Efficacy of Parecoxib in Patients With Subarachnoid Hemorrhage (PARISAH)
- Author
-
Masaryk University and CZECRIN - Czech Clinical Research Infrastructure Network
- Published
- 2024
6. Preemptive Analgesic Efficacy of Parecoxib for Reducing Postoperative Pain in Patients Undergoing Gynecological Surgery.
- Author
-
Tuangjaruwinai, Pasu and Thitisagulwong, Siriporn
- Subjects
GYNECOLOGIC surgery ,POSTOPERATIVE pain ,LENGTH of stay in hospitals ,VISUAL analog scale ,PAIN measurement - Abstract
Objective: This study aimed to evaluate the effectiveness of preemptive parecoxib in reducing postoperative pain following gynecological surgery. Materials and Methods: A double-blind, randomized study involved 168 patients undergoing laparotomy gynecological procedures, including total hysterectomy, adnexal surgery, and surgical staging, between November 2023 and July 2024. Patients were randomly assigned to receive either intravenous parecoxib (n = 82) or normal saline (n = 86) 15 minutes before surgery. Postoperative pain was measured using a visual analog scale at 2, 6, 12, and 24 hours. Morphine consumption within the first 24 hours post-surgery was recorded, along with any adverse events related to parecoxib and the length of hospital stay. Results: Mean pain scores at 2, 6, 12, and 24 hours postoperatively were lower in the treatment group compared to the control group (5.3 vs. 5.7, p = 0.261; 3.7 vs. 5.0, p < 0.001; 3.3 vs. 5.1, p < 0.001; 3.5 vs. 4.0, p = 0.164, respectively). The mean 24-hour postoperative morphine consumption was significantly lower in the treatment group (4 ± 8 mg vs. 8 ± 5 mg, p < 0.001). No significant adverse events occurred between the groups. The total length of hospital stay was similar between the two groups (3.4 ± 1.8 vs. 3.5 ± 1.4 days, p = 0.698). Conclusion: Preemptive parecoxib significantly reduced pain at 6 and 12 hours post-surgery and reduced morphine use within 24 hours, with no significant effect on hospital stay duration in gynecological surgery. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Parecoxib inhibits tumorigenesis and angiogenesis in hepatocellular carcinoma through ERK–VEGF/MMPs signaling pathway.
- Author
-
Tian, Li, Huang, YuQi, Liu, Yan, and Liu, JiangWei
- Subjects
- *
ENDOTHELIAL growth factors , *CELL cycle , *CELL migration , *MATRIX metalloproteinases , *CELL analysis - Abstract
Parecoxib, a well‐recognized nonsteroidal anti‐inflammatory drug, has been reported to possess anticancer properties in various tumor types. In this work, we aimed to investigate the potential anticancer effects of parecoxib on hepatocellular carcinoma (HCC) cells. To assess the impact of parecoxib on HCC cell proliferation, we employed Cell Counting Kit‐8, colony formation, and 5‐ethynyl‐2′‐deoxyuridine assays. Hoechst/propidium iodide (PI) double staining and flow cytometry were performed to evaluate apoptosis and cell cycle analysis. Wound healing and transwell assays were utilized to assess cell migration and invasion. Tube formation assay was employed to analyze angiogenesis. Protein levels were determined using western blotting, and mRNA expression levels were assessed using quantitative real‐time polymerase chain reaction (PCR). A xenograft mouse model was used to confirm the antitumor effects of parecoxib on HCC tumors in vivo. Our data demonstrated that parecoxib effectively inhibited the proliferation of HCC cells in a dose‐ and time‐dependent manner. In addition, parecoxib induced cell cycle arrest in the G2 phase and promoted apoptosis. Moreover, parecoxib hindered tumor migration and invasion by impeding the epithelial–mesenchymal transition process. Further investigation showed that parecoxib could significantly suppress angiogenesis through the inhibition of extracellular signal‐regulated kinase (ERK)–vascular endothelial growth factor (VEGF) axis. Notably, treatment with the ERK activator phorbol myristate acetate upregulated the expression of matrix metalloproteinase (MMP)‐2, MMP‐9, and VEGF and reversed the function of parecoxib in HCC cells. Besides, parecoxib displayed its antitumor efficacy in vivo. Collectively, our results suggest that parecoxib ameliorates HCC progression by regulating proliferation, cell cycle, apoptosis, migration, invasion, and angiogenesis through the ERK–VEGF/MMPs signaling pathway. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Accelerated Recovery Following Opioid-free Anaesthesia in Supratentorial Craniotomy
- Author
-
Fresenius Kabi and Dr. Chu Mei Yeen, Principal Investigator, Trainee in Master of Anaesthesiology & Intensive Care
- Published
- 2024
9. Analgesic Effect of Parecoxib Versus Morphine in SCD Patients Presenting to the Emergency Department (PASC)
- Author
-
Armed Forces Hospital, Oman and Usama Al-Khalasi, EM Specialist
- Published
- 2024
10. Effect of Paracetamol and Mannitol Injection on Postoperative Analgesia in Patients With Thoracoscopic Lobectomy
- Published
- 2024
11. Parecoxib Enhances Resveratrol against Human Colorectal Cancer Cells through Akt and TXNDC5 Inhibition and MAPK Regulation.
- Author
-
Chang, Wan-Ling, Yang, Kai-Chien, Peng, Jyun-Yu, Hong, Chain-Lang, Li, Pei-Ching, Chye, Soi Moi, Lu, Fung-Jou, Shih, Ching-Wei, and Chen, Ching-Hsein
- Abstract
In this study, we discovered the mechanisms underlying parecoxib and resveratrol combination's anti-cancer characteristics against human colorectal cancer DLD-1 cells. We studied its anti-proliferation and apoptosis-provoking effect by utilizing cell viability 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, fluorescence microscope, gene overexpression, Western blot, and flow cytometry analyses. Parecoxib enhanced the ability of resveratrol to inhibit cell viability and increase apoptosis. Parecoxib in combination with resveratrol strongly enhanced apoptosis by inhibiting the expression of thioredoxin domain containing 5 (TXNDC5) and Akt phosphorylation. Parecoxib enhanced resveratrol-provoked c-Jun N-terminal kinase (JNK) and p38 phosphorylation. Overexpression of TXNDC5 and repression of JNK and p38 pathways significantly reversed the inhibition of cell viability and stimulation of apoptosis by the parecoxib/resveratrol combination. This study presents evidence that parecoxib enhances the anti-cancer power of resveratrol in DLD-1 colorectal cancer cells via the inhibition of TXNDC5 and Akt signaling and enhancement of JNK/p38 MAPK pathways. Parecoxib may be provided as an efficient drug to sensitize colorectal cancer by resveratrol. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. Comparative Analysis of Ketorolac and Parecoxib for Postoperative Pain Management in Uvulopalatopharyngoplasty.
- Author
-
Hsieh, Cheng-Yu, Sun, Chuan-Hung, Lin, Chung-Ching, and Chou, Yi-Fan
- Subjects
- *
POSTOPERATIVE pain treatment , *SLEEP apnea syndromes , *POSTOPERATIVE pain , *POSTOPERATIVE period , *VISUAL analog scale - Abstract
Background/Objectives: Uvulopalatopharyngoplasty (UPPP) is a prevalent surgical procedure for treating obstructive sleep apnea. Effective postoperative pain management is crucial for patient comfort and recovery. This study aimed to compare the analgesic efficacies of parecoxib and ketorolac in patients undergoing UPPP. Methods: A prospective, randomized, double-blind study was conducted on 83 patients who received either parecoxib (40 mg intravenously every 12 h) or ketorolac (30 mg intravenously every 8 h) for 2 days following UPPP. Postoperative pain and swallowing discomfort were assessed using visual analog scales (VASs) at 4, 24, 48, and 72 h. The time to resume eating and adverse reactions were also recorded. Results: At 24 and 48 h postoperatively, the mean VAS score was significantly higher in the ketorolac group compared to the parecoxib group (5.0 ± 2.3 vs. 3.6 ± 2.2, p = 0.005 and 3.9 ± 2.2 vs. 2.5 ± 1.7, p < 0.001, respectively). However, no significant difference in the mean VAS scores was observed between the two groups at 72 h postoperatively. With regards to postoperative swallowing pain, the ketorolac group exhibited significantly higher mean VAS scores than the parecoxib group at 4, 24, 48, and 72 h postoperatively. Conclusions: Intravenous parecoxib may offer superior analgesic benefits in the early postoperative period, particularly in alleviating swallowing pain, compared to ketorolac in UPPP procedures. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Preemptive Analgesic Efficacy of Parecoxib for Reducing Postoperative Pain in Patients Undergoing Gynecological Surgery
- Author
-
Pasu Tuangjaruwinai and Siriporn Thitisagulwong
- Subjects
Preemptive analgesia ,Parecoxib ,Gynecological surgery ,Postoperative pain ,Medicine - Abstract
Objective: This study aimed to evaluate the effectiveness of preemptive parecoxib in reducing postoperative pain following gynecological surgery. Materials and Methods: A double-blind, randomized study involved 168 patients undergoing laparotomy gynecological procedures, including total hysterectomy, adnexal surgery, and surgical staging, between November 2023 and July 2024. Patients were randomly assigned to receive either intravenous parecoxib (n = 82) or normal saline (n = 86) 15 minutes before surgery. Postoperative pain was measured using a visual analog scale at 2, 6, 12, and 24 hours. Morphine consumption within the first 24 hours post-surgery was recorded, along with any adverse events related to parecoxib and the length of hospital stay. Results: Mean pain scores at 2, 6, 12, and 24 hours postoperatively were lower in the treatment group compared to the control group (5.3 vs. 5.7, p = 0.261; 3.7 vs. 5.0, p < 0.001; 3.3 vs. 5.1, p < 0.001; 3.5 vs. 4.0, p = 0.164, respectively). The mean 24-hour postoperative morphine consumption was significantly lower in the treatment group (4 ± 8 mg vs. 8 ± 5 mg, p < 0.001). No significant adverse events occurred between the groups. The total length of hospital stay was similar between the two groups (3.4 ± 1.8 vs. 3.5 ± 1.4 days, p = 0.698). Conclusion: Preemptive parecoxib significantly reduced pain at 6 and 12 hours post-surgery and reduced morphine use within 24 hours, with no significant effect on hospital stay duration in gynecological surgery.
- Published
- 2024
14. Risk factors of chronic kidney disease in cisplatin-based hyperthermia intraperitoneal chemotherapy
- Author
-
Chih-Chung Cheng, Hung-Chieh Yeh, Pei-Wen Su, Chien-Lin Ho, and Sheng-Chi Chang
- Subjects
Hyperthermic intraperitoneal chemotherapy ,chronic kidney disease ,acute kidney injury ,parecoxib ,cisplatin ,Medical technology ,R855-855.5 - Abstract
AbstractPurpose Cisplatin is commonly prescribed in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancy. Acute kidney injury (AKI) is regarded as a common complication after HIPEC combined with cytoreductive surgery (CRS). However, post-HIPEC chronic kidney disease (CKD) is scarce and less investigated. This study aims to investigate the incidence of CKD following cisplatin-based HIPEC and to analyse the associated risk factors.Materials and Methods From January 2016 to August 2021, a total of 55 patients treated with CRS and cisplatin-based HIPEC for peritoneal carcinomatosis were categorized retrospectively into groups, with and without CKD. Demographics, comorbidity, surgery, postoperative management, and complications were collected to evaluate risk factors for cisplatin-based HIPEC-related CKD. Univariate and multivariate analyses were conducted to confirm the correlation between different variables and CKD occurrence.Results Of the 55 patients, 24 (43.6%) patients developed AKI and 17 (70.8%) patients of these AKI patients progressed to CKD. Multivariate regression analysis identified intraoperative use of parecoxib (Odds Ratio (OR) = 4.39) and intraoperative maximum temperature > 38.5°C (OR = 6.40) as major risk factors for cisplatin-based HIPEC-related CKD occurrence. Though type II diabetes mellitus and intraoperative complications were the independent risk factors of AKI following cisplatin-based HIPEC, but they were not shown in CKD analysis.Conclusion Intraoperative use of parecoxib during cisplatin-based HIPEC emerged as a significant risk factor for postoperative CKD. Clinicians should exercise caution in prescribing parecoxib during HIPEC procedures. Additionally, maintaining intraoperative body temperature below 38.5°C might be crucial to mitigate the risk of CKD development. This study underscores the importance of identifying and preventing specific risk factors to improve long-term renal outcomes in patients undergoing cisplatin-based HIPEC.
- Published
- 2024
- Full Text
- View/download PDF
15. The Relationship Between Interleukin-1β Levels and Visual Analog Scale Value in Preeclampsia Patients Who Received Perioperative C-Sectional Parecoxib With Spinal Anesthesia
- Author
-
Dino Irawan, Yusrawati Yusrawati, Fidel Ganis Siregar, and Dewi Yulianti Bisri
- Subjects
cytokines ,interleukin-1beta ,parecoxib ,preeclampsia ,visual analogue scale ,Medicine - Abstract
Background: Interleukin1β (IL-1β) increases during inflammation and functions as a mediator that terminates endothelial dysfunction and regulates cellular apoptosis in preeclampsia. Parecoxib is a potential agent because of its superiority as an analgesic and anti-inflammatory that can work peripherally and centrally, with minimal side effects on the mother and baby. Objective: This study aimed to determine the relationship between IL-1β levels and visual analog scale (VAS) scores in preeclampsia patients who received parecoxib perioperatively for cesarean section with spinal anesthesia. Methods: Non-experimental cross-sectional research on preeclampsia patients who received perioperative parecoxib and underwent cesarean section with spinal anesthesia as many as 18 people at Arifin Ahmad Hospital, Riau Province, and Bina Kasih Hospital, Pekanbaru. Samples were taken by Consecutive Sampling. Result: There was a moderate negative correlation between IL-1β and VAS (p
- Published
- 2024
- Full Text
- View/download PDF
16. Optimized Acute Pain Control With Parecoxib in Uniportal Video-assisted Thoracoscopic Surgery.
- Published
- 2023
17. Parecoxib and 5-Fluorouracil Synergistically Inhibit EMT and Subsequent Metastasis in Colorectal Cancer by Targeting PI3K/Akt/NF-κB Signaling.
- Author
-
Chang, Wan-Ling, Peng, Jyun-Yu, Hong, Chain-Lang, Li, Pei-Ching, Lu, Fung-Jou, and Chen, Ching-Hsein
- Subjects
COLORECTAL cancer ,REACTIVE oxygen species ,PI3K/AKT pathway ,METASTASIS ,CANCER-related mortality - Abstract
Colorectal cancer is one of the most common causes of cancer mortality worldwide, and innovative drugs for the treatment of colorectal cancer are continually being developed. 5-Fluorouracil (5-FU) is a common clinical chemotherapeutic drug. Acquired resistance to 5-FU is a clinical challenge in colorectal cancer treatment. Parecoxib is a selective COX-2-specific inhibitor that was demonstrated to inhibit metastasis in colorectal cancers in our previous study. This study aimed to investigate the synergistic antimetastatic activities of parecoxib to 5-FU in human colorectal cancer cells and determine the underlying mechanisms. Parecoxib and 5-FU synergistically suppressed metastasis in colorectal cancer cells. Treatment with the parecoxib/5-FU combination induced an increase in E-cadherin and decrease in β-catenin expression. The parecoxib/5-FU combination inhibited MMP-9 activity, and the NF-κB pathway was suppressed as well. Mechanistic analysis denoted that the parecoxib/5-FU combination hindered the essential molecules of the PI3K/Akt route to obstruct metastatic colorectal cancer. Furthermore, the parecoxib/5-FU combination could inhibit reactive oxygen species. Our work showed the antimetastatic capacity of the parecoxib/5-FU combination for treating colorectal cancers via the targeting of the PI3K/Akt/NF-κB pathway. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. Application of multimodal standardized analgesia under the concept of enhanced recovery after surgery in laparoscopic radical colorectal cancer surgery.
- Author
-
Lu Cao, Le Zhang, Baoyu Chen, Likun Yan, Xianpeng Shi, and Lifei Tian
- Subjects
ENHANCED recovery after surgery protocol ,TRACHELECTOMY ,COMBINED modality therapy ,ONCOLOGIC surgery ,COLORECTAL cancer ,PROCTOLOGY - Abstract
Aims: To observe the efficacy and safety of multimodal standardized analgesia in patients undergoing laparoscopic radical colorectal cancer surgery. Methods: A prospective, double-blind, randomized study of patients who were admitted to our hospital between December 2020 and March 2022 with a diagnosis of colorectal cancer and who intended to undergo elective laparoscopic radical colorectal cancer surgery was conducted. The participants were randomly divided into two intervention groups, namely, a multimodal standardized analgesia group and a routine analgesia group. In both groups, the visual analogue scale (VAS) pain scores while resting at 6 h, 24 h, 48 h and 72 h and during movement at 24 h, 48 h and 72 h; the number of patient controlled intravenous analgesia (PCIA) pump button presses and postoperative recovery indicators within 3 days after surgery; the interleukin-6 (IL-6) and C-reactive protein (CRP) levels on the 1st and 4th days after surgery; and the incidence of postoperative adverse reactions and complications were recorded. Results: Compared with the control group, the multimodal standardized analgesia group had significantly lower VAS pain scores at different time points while resting and during movement (P<0.05), significantly fewer PCIA pump button presses during the first 3 postoperative days (P<0.05), and significantly lower IL-6 and CRP levels on the 1st postoperative day (P<0.05). There was no statistically significant difference in the time to out-of-bed activity, the time to first flatus, the IL-6 and CRP levels on the 4th postoperative day or the incidence of postoperative adverse reactions and complications between the two groups (P >0.05). Conclusion: For patients undergoing laparoscopic radical colorectal cancer surgery, multimodal standardized analgesia with ropivacaine combined with parecoxib sodium and a PCIA pump had a better analgesic effect, as it effectively inhibited early postoperative inflammatory reactions and promoted postoperative recovery and did not increase the incidence of adverse reactions and complications. Therefore, it is worthy of widespread clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Effect of parecoxib on postoperative cognitive function and analgesic safety in elderly patients undergoing gastrointestinal tumor resection: A retrospective study
- Author
-
Yongli Li and Yan Peng
- Subjects
Parecoxib ,non-steroidal anti-inflammatory drugs ,postoperative cognitive dysfunction ,gastrointestinal tumor ,analgesia ,elderly ,Biology (General) ,QH301-705.5 - Abstract
Neuroinflammation is associated with the development of postoperative cognitive dysfunction (POCD). Parecoxib has powerful anti-inflammatory and analgesic effects, which may reduce the occurrence of POCD. We hypothesized that parecoxib could reduce the incidence of POCD and relieve postoperative pain without increasing postoperative complications in elderly patients with gastrointestinal cancer. The study analyzed the effect of parecoxib on elderly patients undergoing elective radical resection of gastrointestinal tumors. Patients were divided into the NSAIDs group and the non-NSAIDs group according to whether parecoxib was administered. Demographic and clinical data were collected and compared. The incidence of POCD was set as the primary outcome, and postoperative pain as the secondary outcome. Among the 440 enrolled patients, the POCD incidence rates within 7 days after surgery in the NSAIDs and non-NSAIDs groups were 42.60% and 40.30%, respectively, with no statistically significant difference (P > 0.05). Patients in the NSAIDs group experienced significantly less pain on the first and second days after surgery compared to the non-NSAIDs group (P < 0.05). There were no statistically significant differences in postoperative adverse events between the two groups (P > 0.05). Parecoxib had no significant negative effect on early postoperative cognitive function, effectively alleviating early postoperative acute pain without increasing postoperative complications. The findings have implications for the broader use of parecoxib in postoperative pain management in elderly patients undergoing major surgery.
- Published
- 2024
- Full Text
- View/download PDF
20. Efficacy of Parecoxib Combined With Paracetamol in Mastectomy
- Author
-
Thepakorn Sathitkarnmanee, Associate professor
- Published
- 2023
21. The Effectiveness of Parecoxib on Inflammatory Cytokines, Prostaglandin Levels, and Visual Analogue Scale Value among Preeclamptic Patients that Undergo Caesarean Section.
- Author
-
Irawan, Dino, Yusrawati, Yusrawati, Siregar, Fidel Ganis, and Bisri, Dewi Yulianti
- Subjects
- *
PREECLAMPSIA , *VISUAL analog scale , *CESAREAN section , *PROSTAGLANDINS , *CYTOKINES , *SPINAL anesthesia , *POSTOPERATIVE pain - Abstract
Introduction: Preeclampsia is produced by the maternal immune system and trophoblast proinflammatory cytokines. Effective perioperative analgesics reduce surgery-related pain and inflammation. It explores how parecoxib affects IL-1, IL-6, prostaglandin and VAS in preeclampsia patients who had a spinal anesthesia cesarean. Materials and methods: This experiment uses a 2-group pretest and posttest. Samples were taken consecutively. The study group (n = 18) received parecoxib 40 mg IV bolus every 12 h 4 times and paracetamol 1,000 mg IV infusion every 8 h until 48 h postoperatively, while the control group (n = 18) received placebo NaCl 0.9 % IV bolus every 12 h 4 times and paracetamol 1,000 mg IV drip every 8 to 48 h. Participants' postoperative pain was assessed by VAS before, 12, 24 and 36 h after surgery. Statistical analysis was conducted on biomolecular examination data, including IL-1ß, IL-6, PGE2 and VAS values. Results and discussion: The study group had lower IL-1ß levels than the control group, although the difference was not significant (p > 0.05). In the study group, IL-6 levels were 4,782 ± 5,673 lower than in the control group (6,147 ± 5,957). Study group IL-6 levels were higher than control group values, although not significantly (p > 0.05). The study group had lower PGE2 than the control group, but not significantly (p > 0.05). The study group's mean VAS value was 1.722 ± 1.994, lower than the control group's 1.833 ± 2.007 and not significant (p > 0.05). The study group had considerably lower VAS values than the control group (p < 0.05). Conclusions: In preeclampsia patients who underwent caesarean delivery under spinal anesthesia, parecoxib administration influences IL-1ß levels after 24 h and VAS values after 12 h. It did not affect IL-6 or PGE2 levels in preeclamptic individuals who had spinal anesthesia caesarean sections. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. Parecoxib decreases cellular growth and Bcl‐2 protein levels in primary cultures of keloid fibroblasts.
- Author
-
Grella, Roberto, Lanzano, Giuseppe, Faenza, Mario, Ferraro, Giuseppe, and Pieretti, Gorizio
- Subjects
NONSTEROIDAL anti-inflammatory agents ,IN vitro studies ,WOUND healing ,EPITHELIAL-mesenchymal transition ,DATA analysis ,CHALONES ,APOPTOSIS ,CELL proliferation ,CYCLOOXYGENASE 2 ,FIBROBLASTS ,TISSUE culture ,RESEARCH methodology ,CELL nuclei ,WESTERN immunoblotting ,ANALYSIS of variance ,STATISTICS ,CELL survival ,KELOIDS ,SIGNAL peptides ,CASPASES ,PHARMACODYNAMICS - Abstract
Keloids seem to overexpress cyclo‐oxygenase‐2 (COX‐2), suggesting a role in its deregulated pathway in inducing an altered epithelial‐mesenchymal interaction, which may be responsible for the overgrowth of dermal components resulting in scars or keloid lesions. This study aimed to evaluate the effect of Parecoxib, a COX‐2 inhibitor, on cell growth in fibroblast primary cultures obtained from human keloid tissues. Tissue explants were obtained from patients who underwent intralesional excision of untreated keloids; central fractions were isolated from keloid tissues and used for establishing distinct primary cultures. Appropriate aliquots of Parecoxib, a COX‐2 inhibitor were diluted to obtain the concentration used in the experimental protocols in vitro (1, 10 or 100 μM). Treatment with Parecoxib (at all concentrations) caused a significant decrease in cellular growth from 24 hours onwards, and with a maximum at 72 hours (P <.02). Moreover, at 72 hours Parecoxib significantly reduced cellular vitality. Parecoxib treatment also induced an increase in fragmented nuclei with a maximum effect at 100 μM and a significant decrease in Bcl‐2 and an increase in activated caspase‐3 protein levels at 72 hours compared with control untreated cultures. Our findings suggest a potential use of the COX‐2 inhibitor, Parecoxib, as the therapy for keloids. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. Retrospective analysis of COX-2 inhibitors on SIRS in acute pancreatitis
- Author
-
YANG Haibo, FU Xifeng, TIAN Yanzhang, GAO Fei, ZHANG Binbin, and MO Shaojian
- Subjects
cyclooxygenase-2 inhibitors ,parecoxib ,acute pancreatitis ,systemic inflammatory response syndrome ,Medicine - Abstract
Objective To investigate the effect of cyclooxygenase-2 (COX-2) inhibitor parecoxib on systemic inflammatory response syndrome (SIRS) in patients with acute pancreatitis (AP). Methods A retrospective analysis was performed on 206 AP patients who were treated in Shanxi Norman Bethune Hospital from April 2021 to April 2022. The patients treated with COX-2 inhibitors were assigned to group A (n=100), and the patients treated with other analgesics were assigned to group B (n=106). The patients with SIRS at admission in group A and B were divided into A1 group (n=48) and B1 group (n=49), and those without SIRS were divided into A2 group (n=52) and B2 group (n=57). The incidence of SIRS in each group was compared, including SIRS duration and rating. The organ failure score (Sequential Organ Failure Assessment, SOFA) and serum CRP level on the 4th day of hospitalization, as well as the length of hospitalization, cost, and incidence of complications between group A and group B were compared. Multivariate logistic regression analysis of risk factors for SIRS in patients who did not experience SIRS at admission. Results Compared with those in group B1, the proportion of patients with SIRS duration< 3 days in group A1 increased, and the proportion of patients with SIRS duration≥ 3 days decreased in group A1(P<0.05=. On the 4th day, SIRS score in group A1 was statistically lower than that in group B1 (P<0.01=, and there was no statistical difference in it between two groups on the 8th day (P>0.05). The incidence of SIRS in group A2 was significantly lower than that in group B2 (32.65% vs 52.63%, χ=5.328, P=0.021). In group A, the organ failure assessment score and the serum CRP were statistically lower than those in group B on the 4th day (P<0.05), and the hospital stay and the hospitalization costs were significantly lower than those in group B (P<0.05=. Multivariable logistic regression of patients without SIRS at admission showed that COX-2 inhibitor was a protective factor associated with the occurrence of SIRS (P<0.05). Conclusion For patients with AP, COX-2 inhibitor pareoxib can reduce the incidence of SIRS, which is closely related to the improvement of SIRS and organ failure, but has no significant difference with the analgesic effect of opioids. It can reduce serum CRP and has good cost-effectiveness. COX-2 inhibitor parecoxib is an independent protective factor for the occurrence of SIRS.
- Published
- 2023
- Full Text
- View/download PDF
24. Regional Scalp Block Versus IV Parecoxib for Post-operative Cranioplasty Surgery Pain: A Comparison of Pain Score.
- Author
-
Mohamad Hasyizan Hassan, Senior Lecturer and Neuroanaesthesiologist
- Published
- 2022
25. Risk factors of chronic kidney disease in cisplatin-based hyperthermia intraperitoneal chemotherapy.
- Author
-
Cheng, Chih-Chung, Yeh, Hung-Chieh, Su, Pei-Wen, Ho, Chien-Lin, and Chang, Sheng-Chi
- Subjects
- *
DISEASE risk factors , *HYPERTHERMIC intraperitoneal chemotherapy , *PREOPERATIVE risk factors , *ACUTE kidney failure , *CHRONIC kidney failure - Abstract
Purpose: Cisplatin is commonly prescribed in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancy. Acute kidney injury (AKI) is regarded as a common complication after HIPEC combined with cytoreductive surgery (CRS). However, post-HIPEC chronic kidney disease (CKD) is scarce and less investigated. This study aims to investigate the incidence of CKD following cisplatin-based HIPEC and to analyse the associated risk factors. Materials and Methods: From January 2016 to August 2021, a total of 55 patients treated with CRS and cisplatin-based HIPEC for peritoneal carcinomatosis were categorized retrospectively into groups, with and without CKD. Demographics, comorbidity, surgery, postoperative management, and complications were collected to evaluate risk factors for cisplatin-based HIPEC-related CKD. Univariate and multivariate analyses were conducted to confirm the correlation between different variables and CKD occurrence. Results: Of the 55 patients, 24 (43.6%) patients developed AKI and 17 (70.8%) patients of these AKI patients progressed to CKD. Multivariate regression analysis identified intraoperative use of parecoxib (Odds Ratio (OR) = 4.39) and intraoperative maximum temperature > 38.5°C (OR = 6.40) as major risk factors for cisplatin-based HIPEC-related CKD occurrence. Though type II diabetes mellitus and intraoperative complications were the independent risk factors of AKI following cisplatin-based HIPEC, but they were not shown in CKD analysis. Conclusion: Intraoperative use of parecoxib during cisplatin-based HIPEC emerged as a significant risk factor for postoperative CKD. Clinicians should exercise caution in prescribing parecoxib during HIPEC procedures. Additionally, maintaining intraoperative body temperature below 38.5°C might be crucial to mitigate the risk of CKD development. This study underscores the importance of identifying and preventing specific risk factors to improve long-term renal outcomes in patients undergoing cisplatin-based HIPEC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. The Efficacy and Safety of Parecoxib Multimodal Preemptive Analgesia in Artificial Joint Replacement: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- Author
-
Zhuoqi Ge, Mingnian Li, Yu Chen, Yufeng Sun, Rui Zhang, Jiaxing Zhang, Xue Bai, Yanyan Zhang, and Qi Chen
- Subjects
Analgesia ,Artificial hip replacement ,Artificial knee replacement ,Meta-analysis ,Multimodal preemptive analgesia ,Parecoxib ,Anesthesiology ,RD78.3-87.3 - Abstract
Abstract Background Postoperative pain after artificial joint replacement is intense and remains an unsolved problem. Some studies have shown that parecoxib can provide better analgesia in postoperative multimodal analgesia, however, doubts arise about whether its multimodal preemptive analgesia can reduce postoperative pain. Objectives The purpose of this systematic review and meta-analysis was to evaluate the impact of preoperative injection of parecoxib on postoperative pain in patients undergoing artificial joint replacement. Study Design Systematic review and meta-analysis. Setting Embase, PubMed, Cochrane Library, CNKI, VIP, Wangfang databases were searched to identify relevant randomized controlled trials. The last search was in May 2022. Methods Randomized controlled trials of efficacy and adverse reactions of intra-operative and postoperative injection of parecoxib in artificial joint replacement were collected. The primary outcome was postoperative visual analog scale scores and the secondary outcomes included cumulative postoperative opioid consumption and incidence of adverse reactions. Using the Cochrane systematic review method to screen the studies, evaluate the quality of the included studies, and extract feature information, RevMan 5.4 software performs a meta-analysis of the corresponding research indicators. Results In total, nine studies were involved in the meta-analysis with 667 patients. The trial and control group were given the same dose of parecoxib or placebo at the same time point before and after surgery. The results showed that compared with the control group, the trial group is associated with substantially reduced visual analog scale scores in 24, 48 h at rest (P 0.05). Limitations The major limitation of this meta-analysis relates to some low-quality studies. Conclusions Our results support parecoxib multimodal preemptive analgesia in reducing postoperative acute pain in hip and knee replacement patients, and reduces cumulative opioid consumption without increasing the risk of adverse drug events. Its multimodal preemptive analgesia is safe and effective in hip and knee replacement. PROSPERO Registration CRD42022379672.
- Published
- 2023
- Full Text
- View/download PDF
27. Parecoxib and 5-Fluorouracil Synergistically Inhibit EMT and Subsequent Metastasis in Colorectal Cancer by Targeting PI3K/Akt/NF-κB Signaling
- Author
-
Wan-Ling Chang, Jyun-Yu Peng, Chain-Lang Hong, Pei-Ching Li, Fung-Jou Lu, and Ching-Hsein Chen
- Subjects
parecoxib ,5-fluorouracil ,colorectal cancer ,metastasis ,reactive oxygen species ,PI3K/Akt pathway ,Biology (General) ,QH301-705.5 - Abstract
Colorectal cancer is one of the most common causes of cancer mortality worldwide, and innovative drugs for the treatment of colorectal cancer are continually being developed. 5-Fluorouracil (5-FU) is a common clinical chemotherapeutic drug. Acquired resistance to 5-FU is a clinical challenge in colorectal cancer treatment. Parecoxib is a selective COX-2-specific inhibitor that was demonstrated to inhibit metastasis in colorectal cancers in our previous study. This study aimed to investigate the synergistic antimetastatic activities of parecoxib to 5-FU in human colorectal cancer cells and determine the underlying mechanisms. Parecoxib and 5-FU synergistically suppressed metastasis in colorectal cancer cells. Treatment with the parecoxib/5-FU combination induced an increase in E-cadherin and decrease in β-catenin expression. The parecoxib/5-FU combination inhibited MMP-9 activity, and the NF-κB pathway was suppressed as well. Mechanistic analysis denoted that the parecoxib/5-FU combination hindered the essential molecules of the PI3K/Akt route to obstruct metastatic colorectal cancer. Furthermore, the parecoxib/5-FU combination could inhibit reactive oxygen species. Our work showed the antimetastatic capacity of the parecoxib/5-FU combination for treating colorectal cancers via the targeting of the PI3K/Akt/NF-κB pathway.
- Published
- 2024
- Full Text
- View/download PDF
28. Associations of parecoxib and other variables with recovery and safety outcomes in total knee arthroplasty: insights from a retrospective cohort study
- Author
-
Ching-Yuan Hu, Jen-Hung Wang, Tsung-Ying Chen, and Po-Kai Wang
- Subjects
total knee arthroplasty ,analgesia ,parecoxib ,mobilization ,postoperative pain ,rehabilitation ,Surgery ,RD1-811 - Abstract
BackgroundEarly mobilization post-total knee arthroplasty (TKA) significantly affects patient outcomes. While parecoxib is known to reduce postoperative pain and morphine use with a favorable safety profile, its impact on mobilization timing post-TKA remains uncertain. This retrospective study aims to assess parecoxib's influence on postoperative mobilization timing in TKA patients without compromising safety.MethodsThis study included unilateral TKA patients treated for primary knee osteoarthritis under general anesthesia. We divided the study period into two intervals, 2007–2012 and 2013–2018, to evaluate temporal differences. Both the control group and parecoxib group received standard postoperative oral analgesics and as-needed intramuscular morphine. The control group did not receive parecoxib, while the parecoxib group did. Primary outcomes compared postoperative complications and mobilization timing between groups, with secondary outcomes including length of hospital stay (LOS), Visual Analog Scale (VAS) scores for pain, as-needed morphine use, and postoperative nausea/vomiting.ResultsParecoxib did not increase postoperative complications. Unmatched comparison with patients in controlled group found that patients in parecoxib group had significantly shortened mobilization time (2.2 ± 1.1 vs. 2.7 ± 1.6 days, P
- Published
- 2024
- Full Text
- View/download PDF
29. Studies on in vitro binding of parecoxib to p38MAPK using spectroscopic methods.
- Author
-
Xuejie Li, Kun Huang, and Shan Zhong
- Subjects
- *
ULTRAVIOLET spectroscopy , *TIME-resolved spectroscopy , *CIRCULAR dichroism , *ULTRAVIOLET-visible spectroscopy , *FLUORESCENCE spectroscopy , *AMINO acid residues , *FLUORESCENCE quenching , *BLOOD proteins - Abstract
Purpose: To investigate the interaction between parecoxib and p38MAPK under simulated physiological conditions. Methods: The interaction between parecoxib and p38MAPK was studied under simulated physiological conditions using spectroscopy-based methods. The effect of parecoxib on the microenvironment and conformation of p38MAPK chromophore was studied by synchronous fluorescence spectroscopy, three)dimensional fluorescence, time-resolved fluorescence spectroscopy, circular dichroism spectroscopy, and ultraviolet-visible absorption spectroscopy. Results: Synchronous fluorescence spectroscopy showed that addition of parecoxib changed the structure of p38MAPK and destroyed the original stable structure. Three-dimensional fluorescence spectroscopy showed that the hydrophilicity of the microenvironment in which the fluorescent chromophore is located was enhanced, and the polarity increased such that the serum protein macromolecules tend to be unfolded, and the alpha-helix content reduced. Time-resolved fluorescence spectroscopy showed that the presence of parecoxib hardly affected the fluorescence quenching of p38MAPK, and the combination of parecoxib and p38MAPK forms a stable complex (static quenching). Circular dichroism spectroscopy revealed the combined parecoxib change, the secondary structure of p38MAPK and reduced the alpha-helix content. Ultraviolet-visible absorption spectroscopy revealed changes in the microenvironment of the three amino acid residues as well as the tertiary structure of the protein. Conclusion: The results shows that parecoxib has a significant effect on the structure of p38MAPK. In addition to explicitly inhibiting COX-2 and blocking arachidonic acid synthesis of prostaglandins, it inhibits the pathway involved in p38MAPK. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
30. The Efficacy and Safety of Parecoxib Multimodal Preemptive Analgesia in Artificial Joint Replacement: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
- Author
-
Ge, Zhuoqi, Li, Mingnian, Chen, Yu, Sun, Yufeng, Zhang, Rui, Zhang, Jiaxing, Bai, Xue, Zhang, Yanyan, and Chen, Qi
- Subjects
- *
ARTHROPLASTY , *ARTIFICIAL joints , *COMBINED modality therapy , *RANDOMIZED controlled trials , *TOTAL knee replacement , *ANALGESIA - Abstract
Background: Postoperative pain after artificial joint replacement is intense and remains an unsolved problem. Some studies have shown that parecoxib can provide better analgesia in postoperative multimodal analgesia, however, doubts arise about whether its multimodal preemptive analgesia can reduce postoperative pain. Objectives: The purpose of this systematic review and meta-analysis was to evaluate the impact of preoperative injection of parecoxib on postoperative pain in patients undergoing artificial joint replacement. Study Design: Systematic review and meta-analysis. Setting: Embase, PubMed, Cochrane Library, CNKI, VIP, Wangfang databases were searched to identify relevant randomized controlled trials. The last search was in May 2022. Methods: Randomized controlled trials of efficacy and adverse reactions of intra-operative and postoperative injection of parecoxib in artificial joint replacement were collected. The primary outcome was postoperative visual analog scale scores and the secondary outcomes included cumulative postoperative opioid consumption and incidence of adverse reactions. Using the Cochrane systematic review method to screen the studies, evaluate the quality of the included studies, and extract feature information, RevMan 5.4 software performs a meta-analysis of the corresponding research indicators. Results: In total, nine studies were involved in the meta-analysis with 667 patients. The trial and control group were given the same dose of parecoxib or placebo at the same time point before and after surgery. The results showed that compared with the control group, the trial group is associated with substantially reduced visual analog scale scores in 24, 48 h at rest (P < 0.05), visual analog scale scores in 24, 48, 72 h at movement (P < 0.05), dose of opioid need in trial group is notably lower than that in control group (P < 0.05), but shows no obvious effect on visual analog scale scores in 72 h at rest, and adverse events (P > 0.05). Limitations: The major limitation of this meta-analysis relates to some low-quality studies. Conclusions: Our results support parecoxib multimodal preemptive analgesia in reducing postoperative acute pain in hip and knee replacement patients, and reduces cumulative opioid consumption without increasing the risk of adverse drug events. Its multimodal preemptive analgesia is safe and effective in hip and knee replacement. PROSPERO Registration: CRD42022379672. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
31. Parecoxib vs. Dexketoprofen for the Management of Pain After Cesarean Section.
- Author
-
Osvaldo A. Reyes T., Coordinator of research
- Published
- 2021
32. Multimodal Analgesia with Local Wound Infiltration and Intravenous Parecoxib for Thyroidectomy.
- Author
-
Gau, Tz-Ping, Wu, Sheng-Hua, Huang, Jui-Mei, Lu, Wen-Ling, Huang, Tzu-Yen, Lu, I-Cheng, and Wu, Che-Wei
- Subjects
COMBINED modality therapy ,EXTRAVASATION ,POSTOPERATIVE pain treatment ,THYROIDECTOMY ,CERVICAL plexus ,PAIN management - Abstract
Background and objective: Adequate postoperative pain control is an important component to enhance recovery. Multimodal analgesia with various pain control techniques has been widely used to alleviate postoperative pain. The use of either wound infiltration or a superficial cervical plexus block has been reported to be effective for pain management after thyroid surgery. The present study evaluated the effect of multimodal analgesia using lidocaine wound infiltration combined with intravenous parecoxib for patients monitored after thyroidectomy. Materials and Methods: A total of 101 patients with a multimodal analgesia protocol being monitored after thyroidectomy were enrolled. After the induction of anesthesia, multimodal analgesia was performed through wound infiltration of 1% lidocaine and epinephrine at a ratio of 1:200,000 (5 μg/mL) combined 40 mg intravenous parecoxib before skin excision. Patients were divided into two groups for this retrospective analysis based on the injection dose of lidocaine they received. Patients in Group I (the control, n = 52) received a 5 mL injection solution, while those in Group II (the study, n = 49) received a 10 mL dosage in a time-sequential manner, in accordance with a previous clinical trial. The primary outcome was measuring postoperative pain intensity at rest, as well as during motion and coughing, which was measured at the postoperative anesthetic care unit (PACU) and on the first day after the operation (POD 1) in the ward. Pain intensity was assessed using a numerical rating scale (NRS). The secondary outcomes were postoperative adverse events including anesthetic-related side effects, as well as airway and pulmonary complications. Results: Most of the patients reported no pain or mild pain during the observation period. The patients in Group II had a lower pain intensity during motion than Group I (NRS 1.47 ± 0.89 vs. 1.85 ± 0.96, p = 0.043) when measured at the postoperative anesthetic care unit. Pain intensity during coughing was also significantly lower in the study group than in the control group (NRS 1.61 ± 0.95 vs. 1.96 ± 0.79, p = 0.049) when measured at the postoperative anesthetic care unit. There were no severe adverse events in either of the groups. Only one patient (1.9%) in Group I experienced temporary vocal palsy. Conclusions: The use of lidocaine with an equal volume of intravenous parecoxib provided comparable analgesia with minimal adverse events when monitoring thyroidectomy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
33. Pain Management After Transnasal Transsphenoidal Surgery for Pituitary Adenomas
- Published
- 2020
34. Parecoxib vs Paracetamol in the Treatment of Acute Renal Colic
- Author
-
Amiri Hospital and Ahmed R. EL-Nahas, Professor of Urology
- Published
- 2020
35. Parecoxib as an Adjuvant to Scalp Nerve Blocks for Relief of Post-craniotomy Pain
- Author
-
Fang Luo, Director of Department of Pain Management
- Published
- 2020
36. the Effect of Doctor-nurse-patient Cooperative Analgesic Linkage Program on Movement Evoked Pain
- Published
- 2020
37. Efficacy and safety of parecoxib and flurbiprofen axetil for perioperative analgesia in children: a network meta-analysis
- Author
-
Xi Chen, Pan Chen, Xiao Chen, Min Huang, Kejing Tang, and Qiuyi He
- Subjects
NSAIDs ,parecoxib ,flurbiprofen axetil ,children ,perioperative analgesia ,Medicine (General) ,R5-920 - Abstract
ObjectiveThe aim of this study was to systematically review the efficacy and safety of parecoxib and flurbiprofen axetil for perioperative analgesia in children through Bayesian network meta-analysis.MethodsWe systematically searched PubMed, Embase, Cochrane Library, Web of Science, Sinomed, CNKI, VIP, and Wanfang Data databases on 18 July 2022 to obtain randomized controlled trials comparing perioperative parecoxib or flurbiprofen with placebo or standard treatment for pediatric analgesia. The outcomes were the postoperative pain score and the incidence of adverse events. The Gemtc package of R-4.0.3 and Stata 17.0 were used for Bayesian network meta-analysis.ResultsWe retrieved 942 articles and 49 randomized controlled trials involving 3,657 patients who met the inclusion criteria. Compared with children who received placebo treatment, those who received flurbiprofen axetil had lower pain sores at each time point within 24 h postoperatively, and those who received parecoxib had lower pain sores at each time point within 12 h postoperatively. Compared with children who received tramadol treatment, both the children who received flurbiprofen axetil or parecoxib had lower pain scores at 8 h postoperatively. The ranking results demonstrated that flurbiprofen axetil had significant superiority in reducing pain scores at 2, 4, and 12 h postoperatively, and parecoxib had significant superiority in reducing pain scores at 0, 0.5, 1, 6, 8, and 24 h postoperatively. In terms of safety, compared with children who received placebo, those who received flurbiprofen axetil or parecoxib had a lower incidence of total adverse events and postoperative agitation. Compared with tramadol, flurbiprofen axetil and parecoxib both significantly reduced the incidence of total adverse events and postoperative nausea and vomiting. Compared with flurbiprofen axetil or fentanyl, parecoxib significantly reduced the incidence of postoperative nausea and vomiting. The ranking results showed that parecoxib was advantageous in decreasing the incidence of total adverse events and postoperative nausea and vomiting.ConclusionFlurbiprofen axetil was most effective at reducing pain scores at 2, 4, and 12 h postoperatively. Parecoxib had an advantage in terms of reducing pain scores at 0, 0.5, 1, 6, 8, and 24 h postoperatively, as well as the incidence of total adverse events and postoperative nausea and vomiting.Systematic trial registrationhttps://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=348886, PROSPERO (CRD42022348886).
- Published
- 2023
- Full Text
- View/download PDF
38. Correlation between perioperative parecoxib use and postoperative acute kidney injury in patients undergoing radical mastectomy: a retrospective cohort analysis
- Author
-
Nan Xu, Ke Pang, Sihua Qi, and Hongmei Wang
- Subjects
Acute kidney injury ,Parecoxib ,Mastectomy ,Anesthesiology ,RD78.3-87.3 - Abstract
Abstract Background Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most widely prescribed drugs worldwide. However, the effect of NSAIDS on postoperative renal function is still unclear. Few studies have assessed the effects of parecoxib on renal function. Our aim is to investigate a correlation between parecoxib and the presence or absence of AKI postoperatively after a breast cancer surgery operation. Methods This was a retrospective cohort study that we performed on our hospitalized database. From January 2012 to August 2021, 3542 female patients undergoing radical mastectomy were enrolled, all data including the patients' information and laboratory results were obtained from electronic medical system. The main outcome was the incidence of AKI postoperatively. AKI was defined in accordance with the KDIGO criteria. Study groups were treated with or without parecoxib. Univariable and multivariable logistic regression analyses were performed. Results In our study, about 5.76% experienced AKI. The incidence rate of postoperative AKI (3.49%) within 7 days in the parecoxib group was lower than that in the control group (6.00%, P = 0.05). Compared to the control group, the AKI’s incidence was reduced by 49% (OR = 0.46; 95%CI 0.27–0.97) in parecoxib group in multivariable logistic regression analysis. There was a reduction in the incidence of postoperative AKI in other three subgroups: preoperative eGFR
- Published
- 2022
- Full Text
- View/download PDF
39. Parecoxib inhibits esophageal squamous cell carcinoma progression via the PDK1–AKT pathway
- Author
-
Han-Ming Huang, Xiao-Yu Huang, Shao-Ping Wu, Can-Keng Chen, Xin-Hua He, and Yong-Fa Zhang
- Subjects
Parecoxib ,Mutant p53 ,PDK1–AKT ,ESCC ,Cytology ,QH573-671 - Abstract
Abstract Background Parecoxib plays an important role in inhibition of human cancer. However, the effect of parecoxib on esophageal squamous cell carcinoma (ESCC) is still not well known. The purpose of this study was to investigate the effect of parecoxib on ESCC and its underlying mechanism. Methods RNA-sequence analysis was performed to identify functional alterations and mechanisms. Cell cycle, proliferation, invasion, and migration were assessed using flow cytometry, CCK-8 assay, colony formation, transwell, and wound healing assays. Extracellular matrix (ECM) degradation was detected by substrate gel zymography and 3D cell culture assay. Western blotting was used to detect parecoxib-dependent mechanisms involving cell cycle, proliferation, invasion, and migration. Tumor formation in vivo was detected by mouse assay. Results Functional experiments indicated that parecoxib induced ESCC cell cycle arrest in G2 phase, and inhibited cell proliferation, invasion, and migration in vitro. Western blotting revealed that parecoxib downregulated the phosphorylation levels of AKT and PDK1, as well as the expression of the mutant p53, cyclin B1, and CDK1, while upregulating p21waf1. Parecoxib inhibited matrix metalloproteinase-2 (MMP2) secretion and invadopodia formation, which were related to ECM degradation. Furthermore, we found that parecoxib suppressed ESCC growth in heterotopic tumor models. Conclusion Parecoxib inhibits ESCC progression, including cell cycle, proliferation, invasion, and migration, via the PDK1–AKT signaling pathway.
- Published
- 2022
- Full Text
- View/download PDF
40. Сyclooxygenase-2 Inhibitor Parecoxib Reduces LPS-Induced Activation of BV2 Microglia Cells.
- Author
-
Li, X., Zhou, J. X., Qu, Y. D., and Kuang, X.
- Abstract
We studied the inhibitory effect of cyclooxygenase-2 inhibitor parecoxib on LPS-induced activation of BV2 microglia cells. The optimal dose of parecoxib (80 μmol/liter) was evaluated by the Cell Counting Kit-8. The cells were divided into the following groups: control (intact cells without treatment); LPS (treatment with 1 μg/ml LPS for 6 h), and experimental (pretreatment with 80 μmol/liter parecoxib for 24 h followed by incubation with 1 μg/ml LPS for 6 h). Cell morphology and proliferation and the expression of NLRP3, caspase-1, pro-caspase-1, and IL-1β were assessed. LPS induced significant morphological changes and decreased proliferation of primary BV2 cells in comparison with the control. These changes were prevented by parecoxib pretreatment. LPS significantly increased NLRP3 inflammatory vesicle activation and expression of NLRP3, caspase-1, pro-caspase-1, and IL-1β in comparison with the control group; pretreatment with parecoxib prevented all these changes. Our results suggest that pretreatment with parecoxib inhibited LPS-induced activation of BV2 microglial cells and probably inhibited NLRP3 inflammasome activation. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
41. Parecoxib expresses anti‐metastasis effect through inhibition of epithelial‐mesenchymal transition and the Wnt/β‐catenin signaling pathway in human colon cancer DLD‐1 cell line.
- Author
-
Wong, Chung Hang, Chang, Wan‐Ling, Lu, Fung‐Jou, Liu, Yi‐Wen, Peng, Jyun‐Yu, and Chen, Ching‐Hsein
- Subjects
COLON cancer ,EPITHELIAL-mesenchymal transition ,CANCER cells ,CELL lines ,CELLULAR signal transduction ,WNT signal transduction ,CELL migration - Abstract
Colorectal cancer is the third leading cause of cancer death in Taiwan. Current treatments involve combination of surgical resection, radiation, and chemotherapy. These treatments have demonstrated to increased five‐year survival of a patient with colorectal cancer. However, metastasis is a major capability of cancer cells that causes poor prognosis, recurrence, and even death. Epidemiological and clinical studies have suggested the use of non‐steroidal anti‐inflammatory drugs (NSAIDs) as an effective class of compounds to prevent colon cancer. Parecoxib is an NSAID and the only parenterally administered selective cyclooxygenase (COX)‐2 inhibitor. In this study, we evaluated whether parecoxib inhibits the metastasis of DLD‐1 human colon cancer cells, a COX‐2 null cell line, and the underlying mechanism. Cell migration of the DLD‐1 cells was significantly inhibited by parecoxib treatment as shown by the Transwell migration assay. This enhanced anti‐migration effect was correlated with the attenuated phosphorylation of Akt, expression of vimentin (a mesenchymal marker), and β‐catenin, and corresponded with the upregulated GSK3β and E‐cadherin (an epithelial marker). These findings suggested that parecoxib could inhibit the epithelial‐mesenchymal transition (EMT) and metastasis in human colon cancer cells by downregulating β‐catenin. Thus, parecoxib could provide a novel prospective strategy for a combination treatment with chemotherapeutic drugs against metastasis of human colon cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
42. Early Parecoxib Usage to Decreases Narcotic Requirement and Length of Stay After Traumatic Rib Fracture
- Published
- 2020
43. Parecoxib Versus Celecoxib Versus Oxycodone in Pain Control for Transcatheter Chemoembolization Procedure
- Author
-
Ming Zhao, Professor
- Published
- 2019
44. Efficacy and Safety of Postoperative Intravenous Parecoxib Sodium Followed by Oral Celecoxib in Osteoarthritis Patients
- Author
-
Xisheng Weng, Department of Orthopedics
- Published
- 2019
45. Effect of Intravenous Dynastat on Postoperative Sore Throat
- Author
-
Po-Kai Wang, Head of Pain Management
- Published
- 2019
46. Analgesic effect of paracetamol monotherapy vs. the combination of paracetamol/parecoxib vs. the combination of pethidine/paracetamol in patients undergoing thyroidectomy
- Author
-
Francesk Mulita, Georgios-Ioannis Verras, Fotios Iliopoulos, Charalampos Kaplanis, Elias Liolis, Levan Tchabashvili, Christos Tsilivigkos, Ioannis Perdikaris, Argyro Sgourou, Adamantia Papachatzopoulou, and Ioannis Maroulis
- Subjects
pethidine ,parecoxib ,postoperative pain ,pain assessment ,thyroidectomy. ,Medicine - Published
- 2021
- Full Text
- View/download PDF
47. Parecoxib sodium alleviates ischemia reperfusion‐induced pulmonary injury via inhibiting ERK/NF‐κB and further activating the HIF‐1α pathway.
- Author
-
Guo, Jiantao and Yang, Yiping
- Subjects
- *
CATALASE , *HEMATOXYLIN & eosin staining , *ISCHEMIA , *REACTIVE oxygen species , *GLUTATHIONE peroxidase , *SOFT tissue injuries - Abstract
Introduction: The lungs are extremely vulnerable to ischemia/reperfusion (I/R), which is characterized by intense inflammation, oxidative stress, alveolar damage, and vascular permeability. Parecoxib sodium (Pare) has been shown to exert protective effects against multiple I/R‐induced tissue injuries. However, its role in I/R‐induced lung injury remains unknown. This study aimed to reveal the roles and mechanisms of Pare in pulmonary I/R injury. Methods: Sixty‐six rats were randomly divided into three groups: The sham‐operated group, the pulmonary I/R group, and the Pare‐pretreated I/R group. Pare at 10 mg/kg or saline (vehicle control) were intraperitoneally administered to rats once per day for 5 consecutive days before ischemia. Serum and tissue samples were harvested following 2 h of reperfusion. The oxygenation index (OI) and alveolar‐arterial oxygen partial pressure difference (PA‐aO2) were analyzed. The levels or activities of malondialdehyde, superoxidase dismutase, catalase, glutathione peroxidase, intracellular reactive oxygen species, tumor necrosis factor‐α, interleukin (IL)‐6, and IL‐8 were examined. The mitochondrial membrane potential was measured. The protein expression levels of the extracellular signal‐regulated kinase (ERK), nuclear factor‐κB (NF‐κB) and their phosphorylated forms, and hypoxia‐inducible factor‐1α (HIF‐1α) were detected. Histological changes were observed using hematoxylin and eosin staining. Moreover, the survival rate following pulmonary I/R injury was recorded daily. Results: Pare significantly increased the OI, decreased the PA‐aO2, increased the levels of antioxidants, while decreasing the levels of oxidants, and alleviated mitochondrial dysfunction and the histopathological damage induced by I/R. Furthermore, Pare inhibited the expression of proinflammatory cytokines, suppressed the activation of ERK and NF‐κB, further increased HIF‐1α expression, and significantly improved the rat survival rate. Conclusions: Pare pretreatment attenuated lung I/R injury by inhibiting oxidative stress and the inflammatory response possibly via inhibiting the activation of the ERK/NF‐κB pathway and further activating the HIF‐1α pathway. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
48. Intravenous Parecoxib for Pain Relief after Orthopedic Surgery: A Systematic Review and Meta-analysis.
- Author
-
Li, Xiaofei, Zhou, Pengxiang, Li, Zhengqian, Tang, Huilin, and Zhai, Suodi
- Subjects
- *
ANALGESIA , *ORTHOPEDIC surgery , *POSTOPERATIVE pain treatment , *POSTOPERATIVE period , *POSTOPERATIVE pain , *INTRAVENOUS therapy - Abstract
Introduction: Orthopedic procedures have been associated with increased pain, making perioperative analgesia a major clinical concern. We assessed the efficacy and safety of intravenous parecoxib administration during the perioperative period for postoperative pain relief after orthopedic surgery in adults. Methods: PubMed, Cochrane Library, EMBASE, and clinicaltrial.gov were searched from inception to 23 August 2021 without language restrictions. Randomized controlled trials comparing intravenous parecoxib with placebo or another active treatment for acute postoperative pain in adults after orthopedic surgery were included. The primary outcomes were the pain scores and cumulative morphine consumption. The secondary outcomes included the proportion of patients requiring rescue analgesics and the incidence of adverse events. The meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines and was registered on the International Prospective Register of Systematic Reviews Registration (PROSPERO). Results: Twenty-seven trials (n = 2840) from more than 20 countries involving six types of orthopedic surgery met the inclusion criteria. Compared with placebo, intravenous parecoxib administration led to reductions in postoperative resting pain scores at 6, 12, 24, and 48 h [mean difference (MD) −0.87, 95% confidence interval [CI] −1.71 to −0.03; MD −0.86, 95% CI −1.26 to −0.46; MD −0.57, 95% CI −0.84 to −0.31; MD −0.40, 95% CI −0.69 to −0.11, respectively], postoperative movement pain scores at 24 and 48 h (MD −0.66, 95% CI −1.14 to −0.19; MD −0.78, 95% CI −1.16 to −0.39, respectively), cumulative morphine consumption (MD −11.30 mg, 95% CI −14.79 to −7.81 mg), and the proportion of patients requiring rescue analgesia (relative risk 0.83, 95% CI 0.77–0.89). There was no difference in the incidence of adverse events between groups. Conclusion: Low to moderate evidence indicates that parecoxib might be an effective and safe analgesic in perioperative orthopedic settings. It relieves postoperative orthopedic pain while sparing opioid analgesic consumption without increasing the incidence of adverse events. PROSPERO Registration: CRD42021274939. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
49. RETRACTED ARTICLE:Parecoxib inhibits esophageal squamous cell carcinoma progression via the PDK1–AKT pathway.
- Author
-
Huang, Han-Ming, Huang, Xiao-Yu, Wu, Shao-Ping, Chen, Can-Keng, He, Xin-Hua, and Zhang, Yong-Fa
- Abstract
Background: Parecoxib plays an important role in inhibition of human cancer. However, the effect of parecoxib on esophageal squamous cell carcinoma (ESCC) is still not well known. The purpose of this study was to investigate the effect of parecoxib on ESCC and its underlying mechanism. Methods: RNA-sequence analysis was performed to identify functional alterations and mechanisms. Cell cycle, proliferation, invasion, and migration were assessed using flow cytometry, CCK-8 assay, colony formation, transwell, and wound healing assays. Extracellular matrix (ECM) degradation was detected by substrate gel zymography and 3D cell culture assay. Western blotting was used to detect parecoxib-dependent mechanisms involving cell cycle, proliferation, invasion, and migration. Tumor formation in vivo was detected by mouse assay. Results: Functional experiments indicated that parecoxib induced ESCC cell cycle arrest in G2 phase, and inhibited cell proliferation, invasion, and migration in vitro. Western blotting revealed that parecoxib downregulated the phosphorylation levels of AKT and PDK1, as well as the expression of the mutant p53, cyclin B1, and CDK1, while upregulating p21waf1. Parecoxib inhibited matrix metalloproteinase-2 (MMP2) secretion and invadopodia formation, which were related to ECM degradation. Furthermore, we found that parecoxib suppressed ESCC growth in heterotopic tumor models. Conclusion: Parecoxib inhibits ESCC progression, including cell cycle, proliferation, invasion, and migration, via the PDK1–AKT signaling pathway. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
50. Combination of Epidural Blockade and Parecoxib in Enhanced Recovery After Gastrointestinal Surgery
- Author
-
Xuerong Zhang, Jun Zhu, Bingqian Ye, Ayibuta Yashengaili, Lei Xu, and Xuebin Li
- Subjects
colorectal cancer ,epidural blockade ,parecoxib ,enhanced recovery ,Surgery ,RD1-811 - Abstract
Objective To investigation effects of the combination use of epidural blockade and parecoxib in postoperative recovery of colorectal cancer (CRC) patients. Methods The present prospective single-blinded study included 186 CRC patients who received radical resection during April 2016 to December 2017. All patients were randomized into 3 different groups, the epidural blockade group, the combined-group with both epidural blockade and pre-intravenous injection of parecoxib, and the control group. The mean operative time, bleeding volume, the first out of bed activity time and hospital stay time were recorded. The mini-mental state examination (MMSE) score and Ramsay score were measured for cognitive function and the Visual Analog Score (VAS) was determined for the pain condition. Results The surgery time for the control group was significantly shorter than the other 2 groups (P
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.